|

Evaluation of the Q-Pad hrHPV Test System for Identifying Precancer

RECRUITINGN/ASponsored by Qurasense
Actively Recruiting
PhaseN/A
SponsorQurasense
Started2025-12-01
Est. completion2026-12-31
Eligibility
Age25 Years+
SexFEMALE
Healthy vol.Accepted
Locations4 sites

Summary

The EQUIP Study is testing whether high-risk human papillomavirus (hrHPV), the virus that causes most cervical cancers, can be accurately detected from menstrual blood collected at home. People who have been referred for colposcopy after an abnormal Pap or hrHPV test will use the Q-Pad Kit during their period to collect menstrual samples on a special menstrual pad and mail them to a central laboratory for hrHPV testing. The same participants will have a standard cervical sample collected for routine hrHPV testing and will undergo colposcopy as part of their usual care. By comparing hrHPV results from menstrual samples with results from cervical samples and biopsy findings, the study will evaluate how well the Q-Pad hrHPV Test System detects cervical precancer and will also assess how easy and acceptable it is for participants to use this at-home collection method.

Eligibility

Age: 25 Years+Sex: FEMALEHealthy volunteers accepted
Inclusion Criteria:

* You are 25 years old or older and have an intact cervix.
* You were referred for a colposcopy after an abnormal Pap or HPV screen.
* Your periods come regularly-about every 21-35 days.
* You own a smartphone, have an email address, and can read the Qvin app instructions in English.
* You are willing to sign the consent form (electronically).
* You agree to use a condom for any vaginal intercourse or shared penetrative toy use from Q-Pad collection until the colposcopy visit if engaging with a new sexual partner during this period.

Exclusion Criteria:

* You are pregnant or think you might be.
* You are unwilling or unable to use the two Q-Pads and mail them back (mailing costs are covered).
* You had treatment for cervical pre-cancer (CIN2+)-such as LEEP, cone, or ablation-within the last 12 months.
* You have already joined this study or are in another cervical-screening / HPV study right now.

Conditions12

CancerCervical Cancer (Early Detection)Cervical Cancer Cin GradeCervical Cancer ScreeningHPVHPV (Human Papillomavirus)-AssociatedHPV 16 InfectionHPV DNAHPV InfectionHPV Infections

Locations4 sites

Connecticut

1 site
Planned Parenthood of Southern New England
New Haven, Connecticut, 06511
Danielle Salinas, MSCR203-903-0394danielle.salinas@ppsne.org

Minnesota

1 site
Planned Parenthood North Central States
Minneapolis, Minnesota, 55408
Bridge McKye, MPH651-389-0675bmckye@ppncs.org

Ohio

1 site
Planned Parenthood of Greater Ohio (PPGOH)
Akron, Ohio, 44302
Penny Paxton440-279-8109penny.paxton@ppoh.org

Utah

1 site
Planned Parenthood Association of Utah
Salt Lake City, Utah, 84102
Priscila Monteiro, MS, MBA385-355-1875Priscila.Monteiro@ppau.org

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.